Medical/Pharmaceuticals
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma
SAN FRANCISCO and SUZHOU, China, Feb. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2021-02-09 08:00
9089
Proxima Ventures and Co-win Ventures invest in Bioelectronica® Corporation to accelerate pharmaceutical discovery and development
RENO, Nev., Feb. 9, 2021 /PRNewswire/ -- Bioelectronica Corporation ("Bioelectronica") today announced the closing of an investment by Proxima Ventures and Co-win Ventures to advance the company's innovations in digital biochemistry, from novel assay development to scalable electrofluidics. The ...
2021-02-09 04:46
3646
8 Growth Opportunities in the Healthcare and Life Sciences Industry to Watch Out for in 2021
Frost & Sullivan experts present strategic insights on key trends such as virtual care, vaccines, hospital efficiency solutions, digital biomarkers, and microbiome therapeutics SANTA CLARA, Calif., Feb. 9, 2021 /PRNewswire/ -- Due to the impact of the COVID-19 pandemic, 2020 was an unforgiving b...
2021-02-09 01:43
309
Cooperation Agreement with Terumo Blood And Cell Technologies to Promote and Sell Osteopore Products
Highlights: * Cooperation Agreement with Terumo Blood and Cell Technologies to promote and sell both companies complementary regenerative products inAsia-Pacific. * Terumo Blood and Cell Technologies' products will be used to concentrate a patient's bone marrow and mixed into Osteopore scaffo...
2021-02-08 21:21
2282
Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-08 21:00
7833
Inova Appoints Claude Basset as Chief Product Officer
LYON, France, Feb. 8, 2021 /PRNewswire/ -- Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer. Inova is a French Tech success story that, now in its 10th year, ha...
2021-02-08 16:00
1666
Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)
First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
2021-02-08 15:00
3518
Zamst announces sponsorship with Yuji Nishida, Professional Volleyball Player
TOKYO, Feb. 8, 2021 /PRNewswire/ -- Nippon Sigmax Co., Ltd., owner of Zamst, a
brand of athletic braces and care products headquartered inTokyo, Japan, has
entered a sports sponsorship agreement withYuji Nishida, Japanese men's
professional volleyball player for JTEKT Stings in V.League.
2021-02-08 14:00
6237
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan
TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study inJapan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin). Kyowa Kirin initiated the clinica...
2021-02-08 09:00
3694
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered underwritten pu...
2021-02-06 06:27
9659
Hidrox(R), a proprietary olive polyphenols formulation may help in managing COVID-19 pandemic
HAYWARD, Calif., Feb. 6, 2021 /PRNewswire/ -- Oliphenol LLC, Hayward, California , announces the publication of a discovery focused upon the SARS-CoV-2-inactivating activity of Hidrox®, an olive polyphenols formulation for a potential treatment against SARS-CoV-2 infection. The Paper, "The SARS-C...
2021-02-06 00:17
3247
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprieta...
2021-02-05 21:00
6071
Report offers checkup on health of Chinese people in 2020
HANGZHOU, China, Feb. 5, 2021 /PRNewswire/ -- Over 60 percent of respondents held a positive attitude toward the prospects of China's healthcare system and the potential for technologies, a health report found. China Daily app and DX Doctor (DXY), a health information sharing platform, published...
2021-02-05 13:08
3198
TCAI physicians participate in clinical trial for potential life-saving device for patients with heart rhythm disorders
AUSTIN, Texas, Feb. 5, 2021 /PRNewswire/ -- Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center are among the first in the world to participate in a clinical trial to evaluate a new esophageal protection device designed to make ablation procedures safer for...
2021-02-05 12:20
2853
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
2021-02-05 11:32
6685
DFI Joins Hands with German ACL to Develop Substantial Business Opportunities in the Smart Medical Market
TAIPEI, Feb. 5, 2021 /PRNewswire/ -- DFI, a leading industrial computer manufacturer, has entered a strategic alliance with ACL, a well-known German medical IT hardware manufacturer, and will combine with DFI's 40 years of rich experience in industrial computers. ACL has been famous in the medica...
2021-02-05 09:00
2772
Global survey presented at the Digital Liver Cancer Summit 2021 reveals heavy toll of COVID-19 first wave on liver cancer care
GENEVA, Feb. 5, 2021 /PRNewswire/ -- The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the is...
2021-02-05 07:00
2980
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
2021-02-04 21:00
5473
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
2021-02-04 20:30
2102
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb. 4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Ph...
2021-02-04 18:41
2388
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
